![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Roquette, a global leader in plant-based ingredients and a leading provider of pharmaceutical and nutraceutical excipients, welcomes CPHI Milan attendees to explore the synergistic potential of its expanded excipients portfolio, a year after the acquisition of leading capsule manufacturer, Qualicaps. At the event, Roquette will showcase its new strategic direction through cutting-edge insights, samples and product demonstrations, all of which highlight how together, Roquette and Qualicaps unlock healthier futures. In addition, the company will reveal its latest breakthrough PEARLITOL® 200 INH mannitol, a carrier specifically developed for dry powder inhalers (DPI). Designed to optimize the performance of DPI formulations when harnessed alongside purpose-built Qualicaps capsules, this high-performance excipient provides a tangible example of inter-company synergy and its potential to improve patient care.
Surveying the synergies
Twelve months on from the announcement at CPHI 2023, Roquette’s acquisition of Qualicaps has solidified its position as a leading, end-to-end solutions provider for oral dosage forms. Both companies hold strong positions in their respective markets and stand at the forefront of innovation, universally recognized as top-tier global players. Now, their blended expertise allows Roquette to offer everything from fillers, binders, encapsulants, disintegrants, lubricants and more, as well as the high-quality capsules that house the final product. What’s more, the combination of the companies’ manufacturing assets, supply chain, in-depth customer knowledge and commercial and technical capabilities provide drug producers with a solid, unified foundation for exceptional service quality, wherever they are based.
“It’s incredible to see the impact the acquisition has had in just 12 short months, particularly in terms of knowledge sharing and the exploration of complementary synergies between our companies,” comments Paul Smaltz, Vice President of Pharmaceutical Solutions at Roquette. “Looking to the future, we’ll continue our review of the Roquette and Qualicaps portfolios, searching for new combined solutions to help our customers unlock brighter, better, more innovative treatments for patients.”
PEARLITOL® 200 INH: Optimized for inhalation
Visitors to the Roquette and Qualicaps booth are invited to witness the combined power of the expanded portfolio through the companies’ latest innovation PEARLITOL® 200 INH, a mannitol carrier for dry powder inhalers (DPI). Roquette’s first dedicated solution for inhalation routes of administration, this highly refined mannitol exhibits optimal particle size distribution (PSD) for DPIs, optimizing production efficiency. Like all Roquette excipient solutions, PEARLITOL® 200 INH is inherently safe and compliant with major international pharmacopeia, while its low reducing sugars and non-hygroscopic properties make it suitable for use with a wide array of active pharmaceutical ingredients – even those with high moisture sensitivity. This versatility alongside precise functionality unlocks powerful synergies when paired with Qualicaps’ best-in-class Quali-V®-I plant-based capsules for dry powder inhalers. The optimized powder properties of PEARLITOL® 200 INH combined with precisely engineered capsules designed for superior puncturing, emptying and aerosolization, results in a solution with outstanding performance, supporting the highest standards in inhalation therapy.
Join the experts at booth 6A58 to learn more about this latest launch and explore the expanded potential of the Roquette and Qualicaps portfolio.
